Chang Ting-Shou, Huang Kuang-Yung, Chang Chun-Ming, Lin Chun-Hsuan, Su Yu-Chieh, Lee Ching-Chih
Department of Otolaryngology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, Republic of China; National Defense Medical Center, Taipei, Taiwan, Republic of China; Institute of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan, Republic of China; Division of Rheumatology, Department of Internal Medicine, Department of Surgery, Department of Medical Research, Division of Hematology-Oncology, Department of Internal Medicine, Department of Otolaryngology, Center for Clinical Epidemiology and Biostatistics, and Cancer Center, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan, Republic of China; School of Medicine, Tzu Chi University, Hualian, Taiwan, Republic of China; Department of Life Science and Institute of Molecular Biology, National Chung Cheung University, Chiayi, Taiwan, Republic of China.
Department of Otolaryngology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, Republic of China; National Defense Medical Center, Taipei, Taiwan, Republic of China; Institute of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan, Republic of China; Division of Rheumatology, Department of Internal Medicine, Department of Surgery, Department of Medical Research, Division of Hematology-Oncology, Department of Internal Medicine, Department of Otolaryngology, Center for Clinical Epidemiology and Biostatistics, and Cancer Center, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan, Republic of China; School of Medicine, Tzu Chi University, Hualian, Taiwan, Republic of China; Department of Life Science and Institute of Molecular Biology, National Chung Cheung University, Chiayi, Taiwan, Republic of China
Oncologist. 2014 Sep;19(9):990-8. doi: 10.1634/theoncologist.2014-0013. Epub 2014 Aug 12.
Different results are reported for the relationship between regional variation in medical spending and disease prognosis for acute illness and for cancer. Our objective was to investigate the association between hospital medical care spending intensity and mortality rates in cancer patients.
A total of 80,597 patients with incident cancer diagnosed in 2002 were identified from the National Health Insurance Research Database of Taiwan, Republic of China. The Cox proportional hazards model was used to compare the 5-year survival rates of patients treated at hospitals with different spending intensities after adjusting for possible confounding and risk factors.
After adjustment for patient characteristics, treatment modality, and hospital volume, an association was found between lower hospital spending intensity and poorer survival rates. The 5-year survival rate expressed by hazard ratios was 1.36 (95% confidence interval [CI]: 1.30-1.43, p < .001) for colorectal cancer, 1.18 (95% CI: 1.08-1.29, p < .001) for lung cancer, 1.13 (95% CI: 1.05-1.22, p = .002) for hepatoma, 1.16 (95% CI: 1.07-1.26, p < .001) for breast cancer, and 1.23 (95% CI: 1.10-1.39, p = .001) for prostate cancer.
Our preliminary findings indicate that higher hospital spending intensity was associated with lower mortality rates in patients being treated for lung cancer, breast cancer, colorectal cancer, prostate cancer, hepatoma, or head and neck cancer. The cancer stages were unavailable in this series, and more research linked with the primary data may be necessary to clearly address this issue.
关于急性疾病和癌症的医疗支出区域差异与疾病预后之间的关系,有不同的研究结果报道。我们的目的是调查医院医疗护理支出强度与癌症患者死亡率之间的关联。
从中国台湾地区国民健康保险研究数据库中识别出2002年确诊的80597例新发癌症患者。采用Cox比例风险模型,在调整可能的混杂因素和风险因素后,比较不同支出强度医院治疗的患者的5年生存率。
在调整患者特征、治疗方式和医院规模后,发现医院支出强度较低与生存率较差之间存在关联。以风险比表示的5年生存率,结直肠癌为1.36(95%置信区间[CI]:1.30 - 1.43,p <.001),肺癌为1.18(95% CI:1.08 - 1.29,p <.001),肝癌为1.13(95% CI:1.05 - 1.22,p =.002),乳腺癌为1.16(95% CI:1.07 - 1.26,p <.001),前列腺癌为1.23(95% CI:1.10 - 1.39,p =.001)。
我们的初步研究结果表明,较高的医院支出强度与肺癌、乳腺癌、结直肠癌、前列腺癌、肝癌或头颈癌患者的较低死亡率相关。本系列研究中无法获取癌症分期,可能需要更多与原始数据相关的研究来明确解决这个问题。